Meyka Pro banner
Viridian Therapeutics, Inc.

Viridian Therapeutics, Inc. Fundamental Analysis (NASDAQ: VRDN)

VRDN●NASDAQ
HealthcareBiotechnology
$29.96
$1.48(4.71%)
U.S. Market opens in 33h 52m

Viridian Therapeutics, Inc. Fundamental Analysis (NASDAQ: VRDN)

Viridian Therapeutics, Inc. (NASDAQ: VRDN) shows moderate financial fundamentals with a PE ratio of -7.84, profit margin of -17.24%, and ROE of -69.76%. The company generates $0.0B in annual revenue with strong year-over-year growth of 233.60%.

Key Strengths

Cash Position28.14%
PEG Ratio0.42
Current Ratio14.46

Areas of Concern

ROE-69.76%
Operating Margin-17.81%
We analyze VRDN's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -1321.5/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-1321.5/100

We analyze VRDN's fundamental strength across five key dimensions:

Efficiency Score

Weak

VRDN struggles to generate sufficient returns from assets.

ROA > 10%
-44.09%

Valuation Score

Excellent

VRDN trades at attractive valuation levels.

PE < 25
-7.84
PEG Ratio < 2
0.42

Growth Score

Excellent

VRDN delivers strong and consistent growth momentum.

Revenue Growth > 5%
233.60%
EPS Growth > 10%
16.58%

Financial Health Score

Excellent

VRDN maintains a strong and stable balance sheet.

Debt/Equity < 1
0.42
Current Ratio > 1
14.46

Profitability Score

Weak

VRDN struggles to sustain strong margins.

ROE > 15%
-6975.61%
Net Margin ≥ 15%
-17.24%
Positive Free Cash Flow
No

Key Financial Metrics

Is VRDN Expensive or Cheap?

P/E Ratio

VRDN trades at -7.84 times earnings. This suggests potential undervaluation.

-7.84

PEG Ratio

When adjusting for growth, VRDN's PEG of 0.42 indicates potential undervaluation.

0.42

Price to Book

The market values Viridian Therapeutics, Inc. at 5.93 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

5.93

EV/EBITDA

Enterprise value stands at -7.77 times EBITDA. This is generally considered low.

-7.77

How Well Does VRDN Make Money?

Net Profit Margin

For every $100 in sales, Viridian Therapeutics, Inc. keeps $-17.24 as profit after all expenses.

-17.24%

Operating Margin

Core operations generate -17.81 in profit for every $100 in revenue, before interest and taxes.

-17.81%

ROE

Management delivers $-69.76 in profit for every $100 of shareholder equity.

-69.76%

ROA

Viridian Therapeutics, Inc. generates $-44.09 in profit for every $100 in assets, demonstrating efficient asset deployment.

-44.09%

Following the Money - Real Cash Generation

Operating Cash Flow

Viridian Therapeutics, Inc. generates limited operating cash flow of $-341.96M, signaling weaker underlying cash strength.

$-341.96M

Free Cash Flow

Viridian Therapeutics, Inc. generates weak or negative free cash flow of $-343.90M, restricting financial flexibility.

$-343.90M

FCF Per Share

Each share generates $-3.03 in free cash annually.

$-3.03

FCF Yield

VRDN converts -10.02% of its market value into free cash.

-10.02%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-7.84

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

0.42

vs 25 benchmark

P/B Ratio

Price to book value ratio

5.93

vs 25 benchmark

P/S Ratio

Price to sales ratio

131.000

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.42

vs 25 benchmark

Current Ratio

Current assets to current liabilities

14.46

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.70

vs 25 benchmark

ROA

Return on assets percentage

-0.44

vs 25 benchmark

ROCE

Return on capital employed

-0.49

vs 25 benchmark

How VRDN Stacks Against Its Sector Peers

MetricVRDN ValueSector AveragePerformance
P/E Ratio-7.8430.24 Better (Cheaper)
ROE-69.76%540.00% Weak
Net Margin-1724.06%-2322.00% (disorted) Weak
Debt/Equity0.420.08 Weak (High Leverage)
Current Ratio14.465.59 Strong Liquidity
ROA-44.09%-17516.00% (disorted) Weak

VRDN outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Viridian Therapeutics, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

183.02%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

87.02%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

61.07%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ